|
|
Analysis of mRNA Drug Development and Market Application |
HUANG Ke1,LI Shan-hong2,*() |
1 Beijing Pharma & Biotech Center(BPBC), Beijing 100352, China 2 Zhifeng Technology (Beijing) Co., Ltd., Beijing 100089, China |
|
|
Abstract Messenger RNA (mRNA) is a kind of nucleic acid sequence which can express any protein of interest after its translation and modification in cells. Because of its inherent feature of protein of interest production, mRNA has potential to be used as drugs to treat various diseases, including viral infections, tumors, diseases caused by deficiency or abnormality of a certain protein in vivo, as well as genetic diseases by encoding Cas9 protein which is involved in gene editing. With the great success of mRNA vaccines, mRNA drugs have drawn increasing attention for their application potential. In addition, due to their advantages such as rapid research and development cycle, the ease and rapid large-scale production at low cost, and elimination of insertional mutagenesis and integration risk for the host, mRNA drugs have become the third generation of drugs after small molecule and antibody drugs. In this review, the structural properties and the delivery system of mRNA are introduced, the clinical progress of mRNA therapeutics and domestic mRNA vaccine development are summarized, and the remaining problems to be solved in the market application including research, manufacture and logistics of mRNA therapeutics are discussed, hoping to provide a reference for mRNA drug discovery and manufacturing.
|
Received: 26 October 2022
Published: 04 July 2023
|
|
|
|
[1] |
Dolgin E. The tangled history of mRNA vaccines. Nature, 2021, 597(7876): 318-324.
doi: 10.1038/d41586-021-02483-w
|
|
|
[2] |
Karikó K, Muramatsu H, Welsh F A, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy, 2008, 16(11): 1833-1840.
doi: 10.1038/mt.2008.200
pmid: 18797453
|
|
|
[3] |
Xu S Q, Yang K P, Li R, et al. mRNA vaccine era-mechanisms, drug platform and clinical prospection. International Journal of Molecular Sciences, 2020, 21(18): 6582.
doi: 10.3390/ijms21186582
|
|
|
[4] |
Baden L R, El Sahly H M, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. The New England Journal of Medicine, 2021, 384(5): 403-416.
doi: 10.1056/NEJMoa2035389
pmid: 33378609
|
|
|
[5] |
Polack F P, Thomas S J, Kitchin N, et al. Safety and efficacy of the BNT162b 2 mRNA COVID-19 vaccine. The New England Journal of Medicine, 2020, 383(27): 2603-2615.
doi: 10.1056/NEJMoa2034577
|
|
|
[6] |
Corbett K S, Flynn B, Foulds K E, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman Primates. The New England Journal of Medicine, 2020, 383(16): 1544-1555.
doi: 10.1056/NEJMoa2024671
|
|
|
[7] |
Vogel A B, Kanevsky I, Che Y, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature, 2021, 592(7853): 283-289.
doi: 10.1038/s41586-021-03275-y
|
|
|
[8] |
Zhao H, Wang T C, Li X F, et al. Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman Primates. Signal Transduction and Targeted Therapy, 2021, 6: 438.
doi: 10.1038/s41392-021-00861-4
pmid: 34952914
|
|
|
[9] |
Schoenmaker L, Witzigmann D, Kulkarni J A, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. International Journal of Pharmaceutics, 2021, 601: 120586.
doi: 10.1016/j.ijpharm.2021.120586
|
|
|
[10] |
Ramanathan A, Robb G B, Chan S H. mRNA capping: biological functions and applications. Nucleic Acids Research, 2016, 44(16): 7511-7526.
doi: 10.1093/nar/gkw551
pmid: 27317694
|
|
|
[11] |
Fuchs A L, Neu A, Sprangers R. A general method for rapid and cost-efficient large-scale production of 5' capped RNA. RNA (New York, N Y), 2016, 22(9): 1454-1466.
|
|
|
[12] |
Grudzien-Nogalska E, Jemielity J, Kowalska J, et al. Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells. RNA, 2007, 13(10): 1745-1755.
pmid: 17720878
|
|
|
[13] |
Beverly M, Dell A, Parmar P, et al. Label-free analysis of mRNA capping efficiency using RNase H probes and LC-MS. Analytical and Bioanalytical Chemistry, 2016, 408(18): 5021-5030.
doi: 10.1007/s00216-016-9605-x
pmid: 27193635
|
|
|
[14] |
Henderson J M, Ujita A, Hill E, et al. Correction: cap 1 messenger RNA synthesis with Co-transcriptional CleanCap® analog by in vitro transcription. Current Protocols, 2021, 1(12): e336.
|
|
|
[15] |
Jia L F, Mao Y H, Ji Q Q, et al. Decoding mRNA translatability and stability from the 5' UTR. Nature Structural & Molecular Biology, 2020, 27(9): 814-821.
doi: 10.1038/s41594-020-0465-x
|
|
|
[16] |
Xia X H. Detailed dissection and critical evaluation of the pfizer/BioNTech and moderna mRNA vaccines. Vaccines, 2021, 9(7): 734.
doi: 10.3390/vaccines9070734
|
|
|
[17] |
Presnyak V, Alhusaini N, Chen Y H, et al. Codon optimality is a major determinant of mRNA stability. Cell, 2015, 160(6): 1111-1124.
doi: 10.1016/j.cell.2015.02.029
pmid: 25768907
|
|
|
[18] |
Morais P, Adachi H, Yu Y T. The critical contribution of pseudouridine to mRNA COVID-19 vaccines. Frontiers in Cell and Developmental Biology, 2021, 9: 789427.
doi: 10.3389/fcell.2021.789427
|
|
|
[19] |
Elango N, Elango S, Shivshankar P, et al. Optimized transfection of mRNA transcribed from a d(A/T) 100 tail-containing vector. Biochemical and Biophysical Research Communications, 2005, 330(3): 958-966.
doi: 10.1016/j.bbrc.2005.03.067
|
|
|
[20] |
Adams D, Gonzalez-Duarte A, O’Riordan W D, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med, 2018, 379(1):11-21.
doi: 10.1056/NEJMoa1716153
|
|
|
[21] |
Dobrowolski C, Paunovska K, Hatit M Z C, et al. Therapeutic RNA delivery for COVID and other diseases. Advanced Healthcare Materials, 2021, 10(15): 2002022.
doi: 10.1002/adhm.v10.15
|
|
|
[22] |
Leung A K K, Tam Y Y C, Chen S, et al. Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems. The Journal of Physical Chemistry B, 2015, 119(28): 8698-8706.
doi: 10.1021/acs.jpcb.5b02891
|
|
|
[23] |
Ewe A, Höbel S, Heine C, et al. Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model. Drug Delivery and Translational Research, 2017, 7(2): 206-216.
doi: 10.1007/s13346-016-0306-y
|
|
|
[24] |
Ke X Y, Shelton L, Hu Y Z, et al. Surface-functionalized PEGylated nanoparticles deliver messenger RNA to pulmonary immune cells. ACS Applied Materials & Interfaces, 2020, 12(32): 35835-35844.
|
|
|
[25] |
Vandenbroucke R E, De Geest B G, Bonné S, et al. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(β-amino esters). The Journal of Gene Medicine, 2008, 10(7): 783-794.
doi: 10.1002/jgm.1202
pmid: 18470950
|
|
|
[26] |
Jarzebska N T, Mellett M, Frei J, et al. Protamine-based strategies for RNA transfection. Pharmaceutics, 2021, 13(6): 877.
doi: 10.3390/pharmaceutics13060877
|
|
|
[27] |
王彧, 白岳丘, 田易晓, 等. mRNA疫苗在疾病预防与治疗中的研究进展与展望. 中国生物工程杂志, 2022, 42(10): 51-59.
|
|
|
[27] |
Wang Y, Bai Y Q, Tian Y X, et al. Advances and prospects of mRNA vaccines used in the prevention and therapies of diseases. China Biotechnology, 2022, 42(10): 51-59.
|
|
|
[28] |
Martinez M, Moon E K. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Frontiers in Immunology, 2019, 10: 128.
doi: 10.3389/fimmu.2019.00128
pmid: 30804938
|
|
|
[29] |
Yin X J, Li L H, Fan H X, et al. Correlation between surfactant protein B mRNA expression and neonatal respiratory distress syndrome. Experimental and Therapeutic Medicine, 2012, 4(5): 815-819.
pmid: 23226732
|
|
|
[30] |
Zangi L, Lui K O, von Gise A, et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nature Biotechnology, 2013, 31(10): 898-907.
doi: 10.1038/nbt.2682
pmid: 24013197
|
|
|
[31] |
Mays L E, Ammon-Treiber S, Mothes B, et al. Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism. The Journal of Clinical Investigation, 2013, 123(3): 1216-1228.
doi: 10.1172/JCI65351
|
|
|
[32] |
Leutert M, Entwisle S W, Villén J. Decoding post-translational modification crosstalk with proteomics. Molecular & Cellular Proteomics, 2021, 20: 100129.
doi: 10.1016/j.mcpro.2021.100129
|
|
|
[33] |
Seidah N G, Chrétien M. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides1. Brain Research, 1999, 848(1-2): 45-62.
pmid: 10701998
|
|
|
[34] |
Schlake T, Thran M, Fiedler K, et al. mRNA: a novel avenue to antibody therapy? Molecular Therapy, 2019, 27(4): 773-784.
doi: S1525-0016(19)30088-7
pmid: 30885573
|
|
|
[35] |
Zhang H X, Zhang Y, Yin H. Genome editing with mRNA encoding ZFN, TALEN, and Cas9. Molecular Therapy, 2019, 27(4): 735-746.
doi: 10.1016/j.ymthe.2019.01.014
|
|
|
[36] |
Conway A, Mendel M, Kim K, et al. Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets. Molecular Therapy, 2019, 27(4): 866-877.
doi: 10.1016/j.ymthe.2019.03.003
|
|
|
[37] |
Qiu M, Glass Z, Chen J J, et al. Lipid nanoparticle-mediated codelivery of Cas 9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118(10).DOI:10.1073/pnas.2020401118.
doi: 10.1073/pnas.2020401118
|
|
|
[38] |
Miller J B, Zhang S Y, Kos P, et al. Non-viral CRISPR/cas gene editing in vitro and in vivo enabled by synthetic nanoparticle Co-delivery of Cas 9 mRNA and sgRNA. Angewandte Chemie International Edition, 2017, 56(4): 1059-1063.
|
|
|
[39] |
Whitley J, Zwolinski C, Denis C, et al. Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials. Translational Research, 2022, 242: 38-55.
doi: 10.1016/j.trsl.2021.11.009
|
|
|
[40] |
Kis Z, Kontoravdi C, Shattock R, et al. Resources, production scales and time required for producing RNA vaccines for the global pandemic demand. Vaccines, 2020, 9(1): 3.
doi: 10.3390/vaccines9010003
|
|
|
[41] |
Webb C, Ip S, Bathula N V, et al. Current status and future perspectives on MRNA drug manufacturing. Molecular Pharmaceutics, 2022, 19(4): 1047-1058.
doi: 10.1021/acs.molpharmaceut.2c00010
|
|
|
[42] |
Rosa S S, Prazeres D M F, Azevedo A M, et al. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine, 2021, 39(16): 2190-2200.
doi: 10.1016/j.vaccine.2021.03.038
pmid: 33771389
|
|
|
[43] |
润顺琪, 熊壮壮, 魏应亮, 等. 新冠病毒mRNA疫苗递送系统的中国专利风险. 中国发明与专利, 2022, 19(8): 35-41.
|
|
|
[43] |
Run S Q, Xiong Z Z, Wei Y L, et al. Risk analysis of patent of COVID-19 mRNA vaccine delivery system in China. China Invention & Patent, 2022, 19(8): 35-41.
|
|
|
[44] |
Zhang N N, Li X F, Deng Y Q, et al. A thermostable mRNA vaccine against COVID-19. Cell, 2020, 182(5): 1271-1283.e16.
doi: 10.1016/j.cell.2020.07.024
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|